GP369 GP369 inhibits activation of amplified FGFR2 signaling Authored: Rothfels, K, 2012-02-09 Edited: Rothfels, K, 2012-05-16 Pubmed20709759 Reactome Database ID Release 432067713 Reactome, http://www.reactome.org ReactomeREACT_120964 Reviewed: Ezzat, S, 2012-05-15 Treatment of FGFR2-amplified gastric and breast cancer cell lines with the antibody GP369 inhibits FGFR2 phosphorylation and downstream signaling and suppresses cell proliferation. Treatment of mice with GP369 inhibits the growth of human cancer xenografts carrying activating FGFR2 mutations. The GP369-binding epitope is contained in the ligand-binding region of the receptor, suggesting that the antibody works by disrupting the ligand-dependent activation of amplified FGFR2 (Bai, 2010). Overexpressed FGFR2 homodimers:GP369 Overexpressed FGFR2 homodimers